- >
- Online Doctor >
- HRT & Menopause >
- Femoston Conti
Femoston Conti is a continuous combined hormone replacement therapy (HRT) containing estradiol (estrogen) and dydrogesterone (progestogen). It is indicated for use in postmenopausal women (at least 12 months since last natural period) to relieve menopausal symptoms such as hot flushes, night sweats, and vaginal dryness. It also helps prevent postmenopausal osteoporosis in women at increased risk of fractures.
- Take one tablet daily, at approximately the same time each day.
- Tablets are taken continuously without a break between packs.
- Swallow whole with water; can be taken with or without food.
- If a dose is missed and less than 12 hours have passed, take it as soon as remembered. If more than 12 hours, skip the missed dose and continue as normal.
- Treatment should be reviewed regularly, using the lowest effective dose for the shortest duration consistent with treatment goals.
Femoston Conti should not be used in patients with:
- Known, past, or suspected breast cancer
- Known or suspected oestrogen-dependent tumours (e.g., endometrial cancer)
- Undiagnosed vaginal bleeding
- Untreated endometrial hyperplasia
- Active or previous venous thromboembolism (DVT/PE)
- Known thrombophilic disorders
- Active or recent arterial thromboembolic disease (e.g., stroke, MI)
- Acute liver disease or history of liver disease until liver function normalises
- Known hypersensitivity to any component of the product
Common:
Headache
Nausea
Breast tenderness
Abdominal pain
Back pain
Uncommon/Serious:
Venous thromboembolism (DVT/PE)
Stroke or myocardial infarction
Gallbladder disease
Increased risk of breast cancer (with long-term use)
Irregular breakthrough bleeding or spotting (especially in early months)
Patients should be advised to seek urgent medical attention if they experience symptoms suggestive of thrombosis, stroke, or severe allergic reaction.
